氯吡格雷抵抗相关基因的研究进展  

Research Progress on Related Genes of Clopidogrel Resistance

作　　者：李倩倩 谷秀娟[2] 

机构地区：[1]延安大学医学院,陕西 延安 [2]延安大学附属医院心脑血管病医院,陕西 延安

出　　处：《临床医学进展》2023年第3期3828-3835,共8页Advances in Clinical Medicine

摘　　要：氯吡格雷是一种临床常用的抗血小板药物,其临床疗效存在广泛的个体间差异,一些患者对氯吡格雷表现出耐药性,这种现象被称为氯吡格雷抵抗(CR)。CR受多种因素的影响,个体的基因差异在CR的发生中扮演着至关重要的角色。目前的研究发现基因ABCB1、CYP2C19、PON1、PXR、P2RY12、GCK、PER3和KDR均与CR相关,其中CYP2C19基因多态性研究最多。Clopidogrel is a clinically commonly used antiplatelet drug with wide inter-individual differences in clinical efficacy, and some patients show resistance to clopidogrel, a phenomenon known as clopidogrel resistance (CR). CR is affected by many factors, and individual genetic differences play a crucial role in the occurrence of CR. The current study found that the genes ABCB1, CYP2C19, PON1, PXR, P2RY12, GCK, PER3 and KDR are all associated with CR, among which CYP2C19 gene polymor-phisms are the most studied.

关 键 词：氯吡格雷 氯吡格雷抵抗 基因多态性 

分 类 号：R96[医药卫生—药理学]